



REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

www.elsevier.es/rgmx



ORIGINAL ARTICLE

Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease[☆]



J.K. Yamamoto-Furusho^{*}, A. Sarmiento-Aguilar, N.N. Parra-Holguín, K.E. Bozada-Gutiérrez

Department of Gastroenterology, Inflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Received 28 August 2017; accepted 7 February 2018

Available online 23 May 2018

KEYWORDS

Inflammatory bowel disease;
Integrated follow-up;
Ulcerative Colitis;
Crohn's disease;
Integral care

Abstract

Introduction and aims: During the clinical course of inflammatory bowel disease, different causes can compromise kidney, liver, and bone marrow function and increase the risk for osteoporosis, infections, and neoplasias. The aim of the present study was to describe the follow-up of Mexican patients with inflammatory bowel disease in relation to their vaccination regimen, treatment-associated risks, and cancer screening.

Materials and methods: A retrospective cross-sectional study was conducted within the time frame of February and June 2017. One hundred patients that had a histopathologic diagnosis of inflammatory bowel disease were surveyed about their follow-up vaccination regimen, treatment-associated risks, and cancer screening. SPSS v24 software was employed for the statistical analysis.

Results: One hundred patients with inflammatory bowel disease were studied (90% with ulcerative colitis and 10% with Crohn's disease; 60% women, 40% men): 75% stated that they had no vaccination regimen. A total of 71.4% of the women had at least one Pap smear in their lives and 28.6% did not have them done annually. Twenty-four percent of the patients wore sun block

[☆] Please cite this article as: Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE. Evaluación del esquema de vacunación y cuidados con relación al seguimiento y tratamiento de los pacientes con enfermedad inflamatoria intestinal. Revista de Gastroenterología de México. 2019;84:11–17.

^{*} Corresponding author. Departamento de Gastroenterología, Clínica de Enfermedad Inflamatoria Intestinal, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15, Colonia Sección XVI, Tlalpan, CP 14000, Mexico City, Mexico. Tel.: +54 87 09 00. E-mail address: kazuofurusho@hotmail.com (J.K. Yamamoto-Furusho).

daily. A total of 18.2% of the patients with more than a 10-year progression of ulcerative colitis had an annual colonoscopy. Yearly kidney function was registered in 57.1% of the patients, 92.9% had a yearly complete blood count, and 78.6% had yearly liver function tests. A total of 34.8% of patients had no bone densitometry in their case records.

Conclusions: These results are a red flag suggesting the need to reinforce the role of the primary healthcare providers in relation to vaccination follow-up and the need to improve the education of the patient in relation to inflammatory bowel disease.

© 2018 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Enfermedad inflamatoria intestinal;
Seguimiento integral;
Colitis ulcerosa crónica idiopática (CUCI);
Enfermedad de Crohn (EC);
Cuidado integral

Evaluación del esquema de vacunación y cuidados con relación al seguimiento y tratamiento de los pacientes con enfermedad inflamatoria intestinal

Resumen

Introducción y objetivos: Durante el curso clínico de la enfermedad inflamatoria intestinal (EII) diversas causas pueden comprometer la función renal, hepática y medular e incrementar el riesgo de osteoporosis, infecciones y neoplasias. El objetivo de este estudio es describir el seguimiento que llevan los pacientes mexicanos con EII respecto a su esquema de vacunación, riesgos asociados a tratamiento y cáncer.

Material y métodos: Estudio transversal, retrospectivo. Se encuestó a 100 pacientes con diagnóstico histopatológico de EII entre febrero y junio de 2017 acerca del seguimiento de esquema de vacunación, riesgos asociados al tratamiento y cáncer. Se realizó el análisis estadístico en SPSS v. 24.

Resultados: Se estudiaron 100 pacientes con EII (el 90% con colitis ulcerosa crónica idiopática, y el 10% con enfermedad de Crohn; el 60% eran mujeres y el 40%, hombres): el 75% negaron poseer un carnet de vacunación; el 71.4% de las mujeres se habían realizado al menos una citometría cervical en su vida, el 28.6% no se la realizan de forma anual; el 24% utilizan protector solar diariamente; el 18.2% con más de 10 años de evolución de una colitis ulcerosa crónica idiopática tiene una colonoscopia anual; anualmente se registra función renal en el 57.1%, biometría hemática en el 92.9%, función hepática en el 78.6% y el 34.8% no tienen densitometría ósea en el expediente.

Conclusiones: Estos resultados son un foco rojo que indica la necesidad de reforzar el papel del primer nivel de atención respecto al seguimiento vacunal y la necesidad de mejorar la educación al paciente con relación a la EII.

© 2018 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Ulcerative colitis (UC) and Crohn's disease (CD) are the 2 main types of inflammatory bowel disease (IBD).¹ Its etiology is still unknown, but it is considered a multifactorial disease, in which the reciprocal interactions between the genetics of the host, environmental factors, the microbiota, and immune responses that normally would mediate mucosal homeostasis, appear deregulated and induce or perpetuate chronic inflammation.^{2,3} Patients diagnosed with IBD require the use of drugs that have different risks, including the 5-aminosalicylates that are used as first-line treatment.^{4,5} Moreover, at some time, 80% of the patients will require treatment with corticosteroids, 40% with thiopurines, and around 20% with biologic drugs. Therefore, due to the medications they receive and the intrinsic factors

of the disease, patients with IBD have an increased risk for acquiring infections,^{6,7} diseases that are preventable through vaccination,⁸ and the development or recurrence of cancer.^{9,10}

The safety profile of the aminosalicylates, especially mesalazine, is similar to that of placebo, but they are not exempt from risks, such as nephrotoxicity, interstitial nephritis, or allergy,¹¹ and therefore annual kidney function control is recommended.¹² Thiopurines have some dose-independent adverse effects, such as the development of pancreatitis, and predisposition to it can only be determined through genetic studies and preventing their use in selected cases. Other adverse effects are dose-dependent, such as myelotoxicity and hepatic toxicity, which we should monitor through complete blood count and liver function tests before treatment and during treatment follow-up.¹³

Likewise, thiopurine use increases the risk for opportunistic infections and malignancy.^{14,15}

One of the most important risks in IBD, not only due to steroid use, but also to the effect of bone inflammation, malabsorption of calcium and vitamin D, and low body mass index,¹⁶ is the alteration in bone mineral density, whose prevalence varies from 22 to 77% for osteopenia and from 17 to 41% for osteoporosis.¹⁷ The use of those drugs can also present, albeit less frequently, risks for glaucoma and cataracts.¹⁶ Finally, biologic treatment results in an increased risk for latent tuberculosis, among other things, making it necessary to perform a tuberculin test or an interferon-gamma release assay before treatment and every year during treatment.⁶

Likewise, the use of those types of drugs and the intrinsic factors involved in IBD increase the risk for skin cancer, and so patients should be advised to use broad-spectrum sunscreen.¹⁸ In relation to UC, there is also an increased risk for colon cancer, making it necessary to have annual control colonoscopy starting from the eighth year of disease progression.¹⁹ Women in particular are at greater risk for presenting with abnormal Pap smears associated with human papillomavirus²⁰ and cervical cancer, underlining the importance of strict follow-up through annual cervical cytology.²¹ With respect to infectious risks, some are preventable through vaccines.¹⁶ Nevertheless, it appears that only 14% of gastroenterologists adequately inform their patients with IBD about vaccinations to prevent those diseases.²²

There are no studies that guide the follow-up of those aspects in Mexican patients with IBD. Therefore, the aim of the present study was to describe the follow-up of Mexican patients with IBD in relation to their vaccination regimen, the risks associated with treatment, and the risk for cancer.

Materials and methods

A retrospective, cross-sectional study was conducted within the time frame of February and June 2017. One hundred patients with the definitive diagnosis of IBD from the IBD Clinic of the *Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán* were interviewed. Other clinical, sociodemographic, and laboratory data were retrospectively collected from the case records for their later concentration and analysis using the SPSS v24 software.

Active patients at the IBD Clinic consultation were asked if they kept a vaccination record card as an important document at home; if they remembered having had the following vaccines and their application dates: chicken pox, herpes zoster, measles/mumps/rubella, diphtheria and pertussis, tetanus, influenza, human papillomavirus, hepatitis A, hepatitis B, meningococcal vaccine, pneumococcal vaccine; and in the case of women, if they had ever had a Pap smear, the last date of the test, if they knew the test result, the frequency with which they had a Pap smear (every year, every 2 years, every 3 years, every 5 years, or at intervals greater than 5 years); if the patients visited a dermatologist (once in their lives, once a year, once every 2 years, or never); if they wore sunscreen daily; and if they smoked or not, the number of years they had smoked, and the number of cigarettes smoked a day to calculate the

smoking index (the number of cigarettes a day times the number of years smoking, divided by 20).

Other clinical and sociodemographic data were collected from the case records and they included: age, sex, histopathologic diagnosis of UC or CD, clinical pattern of CD (inflammatory, stricturing, or fistulizing), as well as the extension of UC (proctitis, proctosigmoiditis, left colitis, or pancolitis), the number of years of disease progression, a family history of colon cancer, cervical cancer, or skin cancer, a personal history of diabetes, dyslipidemia, cataracts, or glaucoma; the presence of extraintestinal manifestations, such as arthritis, arthralgias, sacroiliitis, ankylosing spondylitis, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, or uveitis; the tuberculin test or purified protein derivative (PPD) skin test recorded in the case record, as well as the date and result (positive >10 mm or negative <10 mm), and finally, if they had ophthalmology or dermatology follow-up (at least one note in the case file, once a year, once every 2 years, or never), and the documented diagnosis of cataracts, glaucoma, or avascular necrosis of the head of the femur as a consequence of steroid use.

With respect to laboratory follow-up, the interval (once a year, once every 3 years, or every 5 years or more) between complete blood count, kidney function tests (urea, creatinine), and liver function tests (total bilirubin, direct bilirubin, indirect bilirubin, and transaminases) were registered. The results of hip and spinal densitometry (classifying the result as normal, osteopenia, osteoporosis, or not documented) were also registered, along with the date and report of the last colonoscopy and intervals between the registered studies (maximum every year, maximum every 3 years, or every 5 years or more, or not documented) and the history or presence of colon cancer registered in the case record.

Finally, the data were collected on the pharmacologic treatment of IBD, such as current and previous treatments stated in the clinical history (aminosalicylates, steroids, immunomodulators, or biologic agents), including the mean doses, years of treatment, and calculation of the accumulated dose of each drug (number of treatment days times the mean dose).

Results

One hundred patients with IBD were interviewed. Ninety percent of them had UC and 10% had CD, 60% were women, and 40% were men. In relation to vaccination regimen follow-up, it was striking that 75% of the patients stated they did not have an immunization record card. The demographic characteristics and vaccination history are detailed in [Table 1](#).

[Table 2](#) describes the surveillance of risks associated with medication use. Eighty-four percent of the patients were treated with 5-aminosalicylates. Of those patients, 57.1% had annual kidney function tests, 38.1% had them every 3 years, and 4.8% had them every 5 years or more. Forty-six percent of the patients were treated with steroids. Of those patients, none had cataracts, glaucoma, or femoral head avascular necrosis, 4.3% of them had at least one note per year from the ophthalmology service, 34.8% had no register

Table 1 Demographic characteristics of Mexican patients with inflammatory bowel disease and their vaccination regimen follow-up history.

	UC n = 90 (%)	CD n = 10 (%)	P UC vs CD
Demographic characteristics			
<i>Sex</i>			
Female	52 (52)	8 (80)	0.174
Male	38 (38)	2 (20)	
<i>Age, mean ±SD</i>	44.53 ±14.99	50.70 ± 14.28	0.888
<i>Years of disease progression, median (range)</i>	10 (1-39)	9 (1-22)	0.791
Vaccination history			
<i>Stated having a vaccination card</i>	23(25.6)	2 (20)	0.7
<i>Remembered they had the vaccination for:</i>			
Chicken pox	11 (12.2)	4 (40)	0.02
Herpes zoster	1 (1.1)	0 (0)	0.738
Measles/mumps/rubella	17 (18.9)	3 (30)	0.405
Diphtheria and pertussis	16 (17.8)	5 (50)	0.018
Tetanus	60 (66.7)	7 (70)	0.832
Influenza	44 (48.9)	7 (70)	0.205
Human papillomavirus	4 (7.7)	1 (10)	0.647
Hepatitis B	12 (13.3)	7 (70)	0.161
Hepatitis A	1 (1.1)	2 (20)	0.001
Meningococcal vaccine	0 (0)	1 (10)	0.003
Pneumococcal vaccine	4 (4.5)	1 (10)	0.451

of bone densitometry in their case records, 15.2% had one every year, and 32.6% had one every 5 years or more. Twenty-eight percent of the patients were treated with thiopurines. Of those patients, 92.9% had at least one complete blood count yearly and 78.6% had annual liver function tests. Three percent of the patients were treated with biologic agents, all of whom had a negative PPD skin test.

With respect to the surveillance and prevention of the development of cancer, detailed in Table 3, 71.4% of the women stated they had had at least one Pap smear in their lifetimes, 28.6% did not have it done annually, and 14.3% had a Pap smear every 3 years, but none of them reported positivity for human papillomavirus infection. Seventeen percent of the patients stated they visited the dermatologist at least once a year and 24% wore sunscreen daily. Eighteen percent of the patients were smokers. Upon analyzing those variables in relation to thiopurine use, 3.6% of the patients that took those drugs saw a dermatologist at least every 2 years and 21.4% wore sunscreen daily. Likewise, 28.5% had an annual Pap smear. A total of 18.2% of the patients with disease progression of more than 10 years had a yearly colonoscopy and none of them had a personal history of colon cancer.

Discussion and conclusions

Seventy-five percent of the Mexican patients with IBD did not have an immunization record card, 28.6% of the female patients did not have an annual Pap smear, and 16.3% of the patients with disease progression of more than 10 years had one annual colonoscopy. Those results suggest the need for reinforcing the role of the primary healthcare provider and

the gastroenterologist in educating the patient about his or her disease and the importance of vaccination follow-up, so that he or she has a greater commitment to IBD follow-up, thus facilitating the road to remission. That responsibility does not belong only to the subspecialist, given that surveillance and follow-up are also part of primary healthcare.¹⁶

In the present study, 75% of the patients with IBD did not have an immunization record card. The vaccines most frequently applied were those for tetanus and influenza (66.7 and 70%, respectively). It is known that the low vaccination rates reflect the lack of awareness about vaccination on the part of the patient with IBD, which places that population at a substantial risk for developing infections.²³

There are numerous obstacles to increasing the vaccination rates, such as general apathy, fear and concern about the side effects of vaccination, and even logistic barriers of healthcare center location, as well as the long waiting period to see a physician.²⁴ One of the limitations of the present study to objectively know the vaccination regimen of each patient, was the fact that the majority of the patients did not have an immunization record card. Therefore, the importance of that document needs to be stressed to the patients.²⁵ One of the strategies to get patients interested in vaccination is to educate them in a simple and practical manner about the opportunistic infections they can acquire, such as chicken pox, herpes zoster, influenza, pneumococcal pneumonia, diphtheria and tetanus, hepatitis B, and meningococcal infections. Fatal cases of those infections have been reported in patients with IBD.²⁵⁻²⁹

Regarding the surveillance of adverse effects of the medications used, in the present study it appears that there is good laboratory follow-up in general, with annual complete blood count, liver function tests, and kidney function tests.

Table 2 Surveillance of risks associated with medication use in Mexican patients with inflammatory bowel disease.

	5-aminosalicylates N = 84 (%)	No 5-aminosalicylates N = 15 (%)	p
<i>KFT interval</i>			0.224
Every year	48 (57.1)	12 (80)	
Every 3 years	32 (38.1)	3 (20)	
Every 5 years	4 (4.8)	0 (0)	
	Steroids N = 46 (%)	No steroids N = 54 (%)	p
<i>Ophthalmology follow-up</i>			0.082
Never	44 (95.7)	46 (85.2)	
One ophthalmology note	2 (4.3)	8 (14.8)	
<i>Densitometry</i>			0.592
Normal	13 (43.3)	13 (50)	
Osteopenia	12 (40)	11 (42.3)	
Osteoporosis	5 (16.7)	2 (7.7)	
<i>Densitometry interval</i>			0.223
Never	16 (34.8)	28 (51.9)	
Every year	7 (15.2)	7 (13)	
Every 3 years	8 (17.4)	5 (9.3)	
Every 5 years	15 (32.6)	14 (25.9)	
	Thiopurines N = 28 (%)	No thiopurines N = 72 (%)	p
<i>CBC interval</i>			0.130
Every year	26 (92.9)	71 (98.6)	
Every 3 years	2 (7.1)	1 (1.4)	
<i>LFT interval</i>			0.821
Every year	22 (78.6)	56 (77.8)	
Every 3 years	6 (21.4)	15 (20.8)	
	Biologic agent N = 3 (%)	No biologic agent N = 97 (%)	p
PPD skin test	3 (100)	24 (24.7)	0.735

CBC: Complete blood count; KFT: Kidney function tests; LFT: Liver function tests PPD: Purified protein derivative

However, patients with IBD also have an increased risk for developing skin cancer, uveitis and episcleritis, glaucoma, or cataracts.³⁰⁻³² The results of the present study revealed that less than 10% of the patients were seen by an ophthalmologist or dermatologist, and therefore we emphasize the importance of follow-up by those specialists.

Thirty percent of the patients in our study had a bone densitometry at some point in the course of their disease, which we find alarming, given that IBD patients have an increased risk for developing osteoporosis or osteopenia, not only because of steroid use, but also because of their higher risk for presenting with vitamin D and calcium deficiencies, in addition to the intrinsic factors of the disease and their consequent chronic inflammation.^{33,34} Therefore, we suggest that gastroenterologists reinforce the performance of routine bone densitometry, meaning every year.

In the specific cases of patients in whom pharmacologic treatment with a biologic agent is indicated, before beginning treatment, a PPD skin test is suggested, to rule out

latent tuberculosis,^{35,36} and to administer the adequate drug treatment before using the biologic agent.^{35,37} In our sample of patients with IBD that were given a biologic agent, a PPD skin test and chest x-ray were registered, demonstrating adequate surveillance in that respect.

Eighty-one percent of the women in the present study had an annual Pap smear, but there is an area of opportunity and improvement in relation to the 19% of women who do not.

Only 18.2% of our study patients with more than 10 years of UC progression had a yearly colonoscopy for dysplasia surveillance. The increased risk for colorectal cancer in IBD patients makes that result important. Cancer is the second most common cause of death in those patients, even though the rates of colorectal cancer have been decreasing. Patients with IBD are recommended to have surveillance colonoscopy 8-10 years after symptom onset. Surveillance colonoscopies should be performed in 1 to 3-year intervals, depending on whether the risk is low, intermediate, or high for developing colorectal cancer. Ideally, colonoscopy should

Table 3 Surveillance of cancer development in Mexican patients with inflammatory bowel disease.

	Thiopurines N = 28 (%)	No thiopurines N = 72 (%)	p
<i>History of skin cancer</i>	0	2 (2.8)	0.373
<i>Visits the dermatologist at least every 2 years</i>	1 (3.6)	4 (5.6)	0.751
<i>Wears sunscreen daily</i>	6 (21.4)	18 (25)	0.707
<i>History of cervical cancer</i>	0	0	1.0
Had a Pap smear within the last year	16 (57)	29 (40)	0.554
Every year	8 (28.5)	17 (23.6)	0.896
Every 3 years	3 (10.7)	4 (5.5)	
Every 5 years or more	2 (7.5)	2 (2.7)	
	10 or more years of UC progression N = 48 (%)	Fewer than 10 years of UC progression N = 42 (%)	p
<i>History of colon cancer</i>	0	0	1.0
<i>Colonoscopy</i>			0.006
Once a year	8 (18.2)	22 (53.7)	
Once every 2 years	16 (36.4)	6 (14.6)	
Every 3 years	11 (25)	7 (17.1)	
Every 5 years	9 (20.5)	6 (14.6)	

be carried out when the patient is in clinical remission and surveillance should be annual in the patient with endoscopically persistent active disease, a history of dysplasia, a family history of colon cancer in a first-degree relative, or a history of primary sclerosing cholangitis.^{38–40} Thus, we suggest that the physicians treating patients with UC reinforce those measures.

Finally, it is important to emphasize the role each level of healthcare plays, in relation to the patient with IBD, as well as the responsibility each patient has to carry out the recommendations for the follow-up and surveillance of his or her disease and the surveillance of comorbidities that can present during the course of the disease.⁶ The present study underlines the importance of reinforcing follow-up and surveillance at all levels of healthcare, particularly in immunosuppressed patients with IBD. A complete clinical history should be obtained for each patient, with special care given to the family history of hereditary disease, especially in first-line cases of cancer. The vaccination regimen should be objectively evaluated using the immunization record card and adequate follow-up and surveillance of adverse effects from medications and risks for the disease should be carried out, as well as multidisciplinary management including the areas of dermatology and ophthalmology.^{6,16}

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Financial disclosure

No specific grants were received from public sector agencies, the business sector, or non-profit organizations in relation to this study.

Conflict of interest

Dr. Jesús Kazuo Yamamoto Furusho is a speaker, opinion leader, and member of the advisory board committees for the following national and international laboratories: Abbvie, Ferring, Hospira, Janssen, Pfizer, and Takeda. He has been or is presently a speaker for the following laboratories: Almirall, Danone, Farmasa, Grunenthal, and UCB. He has been or presently is the main researcher in international projects with the following laboratories: Abbvie, Allergan, Bristol, Ferring, Pfizer, Roche, Shire, and Takeda. He is currently the president of the Pan American Crohn's and Colitis Organisation (PANCCO).

The authors A. Sarmiento-Aguilar, N.N. Parra-Holguín, and K.E. Bozada-Gutiérrez declare that they have no conflict of interest.

References

1. Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. *Lancet*. 2007;369:1627–40.
2. Sartor RB. Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol*. 2006;3:390–407.
3. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. *Gastroenterol*. 2017;152:327–39.
4. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. *J Crohn Colitis*. 2016;1–23.

5. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. *J Crohn Colitis*. 2017;11:769–84.
6. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohn Colitis*. 2014;8:443–68.
7. Mazzola G, Macaluso FS, Adamoli L, et al. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. *J Infect*. 2017;74:433–41.
8. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledge. *Inflamm Bowel Dis*. 2011;17:2536–40.
9. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. *Gut*. 2014;63:1416–23.
10. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. *Nat Rev Immunol*. 2006;6:715–27.
11. Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. *Dig Dis*. 2013;31:368–73.
12. Zallot C, Billioud V, Frimat L, et al. 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: A nationwide survey. *J Crohns Colitis*. 2013;7:551–5.
13. Macaluso FS, Renna S, Maida M, et al. Tolerability profile of thiopurines in inflammatory bowel disease: A prospective experience. *Scand J Gastroenterol*. 2017;52:981–7.
14. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterol*. 2008;134:929–36.
15. Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. *Am J Epidemiol*. 2013;177:1296–305.
16. Park JR, Pfeil SA. Primary care of the patient with inflammatory bowel disease. *Med Clin North Am*. 2015;99:969–87.
17. Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. *Am J Med*. 2009;122:599–604.
18. De Luca JF, Severino R, Lee YS, et al. Dermatologist and gastroenterologist awareness of the potential of immunosuppressants used to treat inflammatory bowel disease to cause non-melanoma skin cancer. *Int J Dermatol*. 2013;52:955–9.
19. Eluri S, Parian AM, Limketkai BN, et al. Nearly a third of high-grade dysplasia and colorectal cancer is undetected in patients with inflammatory bowel disease. *Dig Dis Sci*. 2017, <http://dx.doi.org/10.1007/s10620-017-4652-5>.
20. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. *Am J Gastroenterol*. 2008;103:631–6.
21. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *Am J Clin Pathol*. 2012;137:516–42.
22. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. *Inflamm Bowel Dis*. 2012;18:34–40.
23. Ojjiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. *J Gastroenterol*. 2008;43:397–401.
24. Reich JS, Farraye FA, Wasan SK. Preventative care in the patient with inflammatory bowel disease: What is new? *Dig Dis Sci*. 2016;61:2205–16.
25. Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. *World J Gastroenterol*. 2014;20:9675–90.
26. Ham M, Cullen G, Cheifetz AS. Varicella zoster virus infection in patients with inflammatory bowel disease. *Gastroenterol Hepatol*. 2013;9:56–8.
27. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Recomm Rep*. 2013;62:1–28.
28. Pan Y, Liu Y, Guo H, et al. Associations between folate and vitamin B12 levels and inflammatory bowel disease: A meta-analysis. *Nutrients*. 2017;9:1–15.
29. Ben Musa R, Gampa A, Basu S, et al. Hepatitis B vaccination in patients with inflammatory bowel disease. *World J Gastroenterol*. 2014;20:15358–66.
30. McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-alpha inhibitor monotherapy and in combination with thiopurines: Analysis of the food and drug administration adverse event reporting system. *J Gastrointest Liver Dis*. 2014;23:267–71.
31. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. *Arch Ophthalmol*. 1997;115:61–4.
32. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2014;12:210–8.
33. Mouli VP, Ananthakrishnan AN. Review article: Vitamin D and inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2014;39:125–36.
34. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911–30.
35. Hong SN, Kim HJ, Kim KH, et al. Risk of incident *Mycobacterium tuberculosis* infection in patients with inflammatory bowel disease: A nationwide population-based study in South Korea. *Aliment Pharmacol Ther*. 2017;45:253–63.
36. Riestra S, de Francisco R, Arias-Guillén M, et al. Risk factors for tuberculosis in inflammatory bowel disease: Anti-tumor necrosis factor and hospitalization. *Rev Española Enfermedades Dig*. 2016;108:541–9.
37. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based Assays for the diagnosis of latent tuberculosis infection: An update. *Ann Intern Med*. 2008;149:177–84.
38. Konijeti GG, Shrive MG, Ananthakrishnan AN, et al. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. *Gastrointest Endosc*. 2014;79:455–65.
39. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology*. 2017;138:738–45.
40. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Libr*. 2013;19:860–3.